The goal of Firefly is to take the Company's patented molecular diagnostic technology underlying M-BAND, and implement it in a handheld device that can be used anywhere, anytime to test for biological agents. Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in less than 15 to 30 minutes depending on the type of test performed. Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application. The Company believes the target markets for Firefly include military field deployments, remote areas with limited or no access to healthcare, border locations and others.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid medical testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. http://www.PositiveIDCorp.com
Statements about PositiveID's future expectations, including, without limitation, the likelihood that results from M-BAND are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments; the likelihood that Firefly takes the Company's patented molecular diagnostic technology underlying the M-BAND system, and implements it in a handheld device that can be used anywhere, anytime for rapid biological testing; the likelihood that Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in 15 to 30 minutes depending on the type of test performed; and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the biological detection and diagnostic sectors; the Company's ability to attract the research and development capital to complete the development of Firefly; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 16, 2013 under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed May 2013 for three months: $1500 plus 50,000 144 shares .
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
No comments:
Post a Comment